Latest 8-K filings

NeoGenomics, Inc. announced the departure of its EVP, General Counsel & Business Development, Alicia Olivo, effective September 21, 2026.

High Roller Technologies reported second quarter 2026 results, noting progress in its U.S. prediction markets launch with regulatory approvals and strategic partnerships, alongside a revenue decrease and increased operating loss.

H&R Block announced fiscal 2026 results, highlighting a 5% revenue increase to $3.95 billion, a 23% rise in operating cash flow, and a 10% dividend hike.

Seneca Foods Corporation's 2026 Annual Meeting saw overwhelming shareholder approval for director elections, executive compensation, and the 2026 Equity Incentive Plan, alongside ratification of Deloitte & Touche LLP.

National CineMedia (NCM) announced its definitive agreement to acquire Captivate Holdings, LLC for $275 million, creating a leading premium video and digital out-of-home advertising platform.

Factorial Energy announced its second quarter 2026 financial and business results, detailing advancements in solid-state battery technology integration and securing its first commercial drone battery order.

DoorDash, Inc. announces stockholder approval for reincorporation from Delaware to Nevada, effective after regulatory filings and waiting periods.

Griffon Corporation announced the pricing of $800 million in senior notes due 2034, carrying a 6.25% interest rate, to refinance existing debt.

Inhibikase Therapeutics announced Q2 2026 results, highlighting progress in its Phase 3 PAH study, positive early data for IKT-001, and a $50 million capital raise.

GrowGeneration Corp. announced its second quarter 2026 financial results, reporting a 5.5% year-over-year increase in net sales and raising its full-year Adjusted EBITDA guidance.

Mineralys Therapeutics reported Q2 2026 financial results, highlighted by ongoing FDA review of lorundrostat with a PDUFA date of December 22, 2026, and a strengthened balance sheet.

Lenz Therapeutics reported $5.5 million in Q2 2026 revenue, driven by VIZZ sales and license agreements, alongside the launch of a new telehealth channel.

Evolv Technology announced robust second quarter financial results, showcasing significant year-over-year revenue growth, improved Adjusted EBITDA, and an optimistic revised forecast for the full year 2026.

SELLAS Life Sciences Group reported Q2 2026 results, highlighting progress in Phase 3 REGAL trial for GPS and Phase 2 for SLS009, with topline data expected Q4 2026, alongside a robust cash reserve of $138.3 million.

Gladstone Land Corporation announced its second quarter 2026 financial results, reporting a net loss of $8.5 million and a net loss attributable to common stockholders of $13.5 million, while also highlighting portfolio activity and debt management.

NeuroPace announced robust second quarter 2026 financial results, driven by significant RNS revenue growth, and has increased its full-year revenue guidance.

Energy Vault Holdings, Inc. reported a strong second quarter of 2026 with revenue up 104% year-over-year, significantly expanded gross margins, and a record contract backlog of $2 billion, leading to raised full-year revenue and gross margin guidance.

NextNav Inc. announced its second quarter 2026 financial results, showcasing strengthened partnerships, significant debt reduction, and a robust cash position.

Black Rock Coffee Bar announced robust second quarter 2026 financial results, featuring 25.0% total revenue growth and a 403.3% increase in net income.

BridgeBio Oncology Therapeutics reported Q2 2026 financial results, highlighting advancements in its clinical programs for RAS-pathway malignancies and a cash runway extending into 2028.

Grove Collaborative Holdings, Inc. received a notice from the NYSE for failing to meet minimum market capitalization and stockholders' equity requirements, necessitating a business plan to regain compliance.

Rocket One Inc. received a Nasdaq delisting warning for failing to meet minimum bid price requirements, while simultaneously announcing its acceptance into the Seagate Partner Program to bolster its AI infrastructure strategy.

Anterix announced its first quarter fiscal year 2027 results, reporting approximately $33.1 million in contracted proceeds and a $10.7 million gain on broadband license exchanges, while maintaining a debt-free balance sheet with $116.0 million in cash.

B&G Foods reported a 9.7% decrease in net sales for Q2 2026 to $383.3 million and a net loss of $4.0 million, though adjusted EBITDA increased by 4.2% to $60.4 million.

Gain Therapeutics announced FDA IND acceptance for rexaceract's Phase 2 trial and reported Q2 2026 financial results, highlighting pipeline progress despite a net loss.

IZEA Worldwide announced its second quarter 2026 financial results, reporting $5.8 million in revenue, a 36% decrease year-over-year, and a net loss of $0.7 million.

Erasca, Inc. announced second quarter 2026 financial results and business updates, highlighting progress in its ERAS-0015 and ERAS-4001 clinical programs and a substantial capital raise.

Snail, Inc. reported its second quarter 2026 financial results, showing a year-over-year revenue decrease but a substantial improvement in net loss, alongside updates on its ARK franchise and new AI ventures.

East West Ave Acquisition Corp. announced that its common stock and rights will begin trading separately on August 14, 2026, offering investors more trading flexibility.

Sanara MedTech Inc. announces an Agreement and Plan of Merger with MiMedx Group, Inc., detailing terms for acquisition and shareholder consideration.